

BIOGNOSYS GRANT PROGRAM



Apply by

February 17th, 2021

Guidelines & Application Form Questions?

biognosys.com/grant-program

grant.program@biognosys.com

Proposals will be reviewed by our panel of experts based on the scientific merit and alignment with Biognosys' strategic domain of focus. We look forward to receiving your application!

2021 | NAFLD & NASH

GAIN ACCESS TO CUTTING-EDGE PROTEOMICS

The Challenge

Non-alcoholic fatty liver disease (NAFLD) is a highly complex disorder caused by various metabolic, inflammatory, and genetic traits. Despite raging prevalence estimated at 25% worldwide, no approved treatment exists. Hence an improved understanding of the molecular mechanisms of this pathology is needed.

The Opportunity

We believe that functional proteomics can provide deeper insights into disease phenotype and better identification of actionable biomarkers resulting in new treatment targets and faster drug-to-market delivery. For this reason, the Grant Recipient will be offered exclusive access to Biognosys' cutting-edge proteomics solutions at no cost for a translational or clinical stage project.

Past Programs

Following the success of our previous Grant Program edition in the field of immuno-oncology with Parker Institute for Cancer Immunotherapy, we are pleased to announce our next Grant Program supporting the fight against the global NAFLD epidemic.

Who we are

Biognosys is the world leader in next generation proteomics. We provide state-of-the-art proteomics solutions, addressing key questions throughout the entire drug development process. Our pioneering role in the field of proteomics has been confirmed by multiple peer-reviewed publications and a broad commercial engagement across the biopharma sector including Roche, Genentech, and Bayer.